| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/21/2013 | US8445634 Method of producing FR901228 |
| 05/21/2013 | US8445627 Alkylene-dicarboxylate-containing biodegradable poly(ester-amides) and methods of use |
| 05/21/2013 | US8445545 Pharmaceutical composition, method of preparation and methods of treating aches/pains |
| 05/21/2013 | US8445237 RNA interference mediating small RNA molecules |
| 05/21/2013 | US8445027 Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and prostamide |
| 05/21/2013 | US8445026 Selenium nanoparticles with improved biological effects |
| 05/21/2013 | US8445025 Hybrid superparamagnetic iron oxide nanoparticles and polyethylenimine as a magnetoplex for gene transfection |
| 05/21/2013 | US8445024 Preparations containing hyperbranched polymers |
| 05/21/2013 | US8445023 Anti-misuse microparticulate oral pharmaceutical form |
| 05/21/2013 | US8445022 Embolization |
| 05/21/2013 | US8445021 Functionalized magnetic nanoparticles and methods of use thereof |
| 05/21/2013 | US8445020 High-loading, controlled-release magnesium oral dosage forms and methods of making and using same |
| 05/21/2013 | US8445019 Microparticle dispersion liquid manufacturing method and microparticle dispersion liquid manufacturing apparatus |
| 05/21/2013 | US8445018 Abuse resistant drug formulation |
| 05/21/2013 | US8445016 Grafted polymers and uses thereof |
| 05/21/2013 | US8445015 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 05/21/2013 | US8445014 Ion binding compositions |
| 05/21/2013 | US8445013 Stable pharmaceutical composition and methods of using same |
| 05/21/2013 | US8445012 Compositions and methods for delivery of embolics |
| 05/21/2013 | US8445011 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 05/21/2013 | US8445010 Abuse potential reduction in abusable substance dosage form |
| 05/21/2013 | US8445009 Processes for the production of solid dressings for treating wounded tissue |
| 05/21/2013 | US8445003 Stable pharmaceutical composition and methods of using same |
| 05/21/2013 | US8445002 Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
| 05/21/2013 | US8444967 Treatment including prebiotic composition for use with probiotics |
| 05/21/2013 | US8444630 Oxygen supply for cell transplant and vascularization |
| 05/21/2013 | US8443799 Dry powder inhalation system for transpulmonary administration |
| 05/21/2013 | CA2809279A1 Natural biocomposite powder prepared from pichia pastoris biomass, method of preparation and its use as excipient |
| 05/21/2013 | CA2579533C Drug delivery from embolic agents |
| 05/21/2013 | CA2565134C Novel oral formulations of ospemifene |
| 05/21/2013 | CA2556993C Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
| 05/21/2013 | CA2545961C Film-forming starchy composition |
| 05/21/2013 | CA2528649C Analgesic and anti-inflammatory patch |
| 05/21/2013 | CA2477675C Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| 05/21/2013 | CA2428753C Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 05/21/2013 | CA2397987C Use of at least a fatty ester for preparing a composition designed to inhibit 5 alpha reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 05/21/2013 | CA2349203C Dispersible phospholipid stabilized microparticles |
| 05/21/2013 | CA2294865C Immunogenic lhrh compositions and methods relating thereto |
| 05/18/2013 | CA2795893A1 Controlled release formulations of tolterodine and process of manufacturing |
| 05/18/2013 | CA2758657A1 Controlled release formulations of tolterodine and process of manufacturing |
| 05/17/2013 | CA2758556A1 Pharmaceutical composition of amphetamine mixed salts |
| 05/16/2013 | WO2013070872A1 Methods and compositions for x-ray induced release from ph sensitive liposomes |
| 05/16/2013 | WO2013070656A1 Sustained release suspension preparation for dextromethorphan |
| 05/16/2013 | WO2013070362A1 Compositions and methods for immune tolerance induction |
| 05/16/2013 | WO2013070324A1 Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| 05/16/2013 | WO2013069897A1 Stabilised sustained-release preparation of sarpogrelate |
| 05/16/2013 | WO2013069821A1 Malignant tumor treatment agent and food and drink including same |
| 05/16/2013 | WO2013069764A1 Method for ingesting creatine composition, creatine composition for use in said ingestion method, and creatine-containing medicinal agent and food each produced using said creatine composition |
| 05/16/2013 | WO2013068625A1 Nanoparticulate systems prepared from sorbitan esters |
| 05/16/2013 | WO2013068565A2 Melatonin-based solutions and powders for their preparation |
| 05/16/2013 | WO2013068513A1 Lubricious coatings |
| 05/16/2013 | WO2013068478A1 New coated controlled release active agent carriers |
| 05/16/2013 | WO2013068399A1 Film packaging for oral biologics |
| 05/16/2013 | WO2013068371A1 Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
| 05/16/2013 | WO2013067882A1 Water-soluble vitamin e derivative modified fat-soluble anti-cancer drug compound and formulation, preparation method and use thereof |
| 05/16/2013 | WO2013067881A1 Water-soluble vitamin e derivative-modified amphiphilic anticancer medicament compound and preparation, method for preparing the compound, and application thereof |
| 05/16/2013 | WO2013067769A1 Liquid composition of anti-hepatitis b virus |
| 05/16/2013 | WO2013067682A1 A hydrocolloid composition and an article containing the same |
| 05/16/2013 | WO2013067612A1 Pharmaceutical composition for the preparation of a drug for treating neuropathic pain, chronic degenerative disease-related pain and post-operative pain in animals |
| 05/16/2013 | WO2013067591A1 Topical formulations for pain management |
| 05/16/2013 | WO2013039994A3 Apparatus, composition, and related methods for transdermal delivery of active ingredients |
| 05/16/2013 | WO2013033400A9 Methods for effectively and rapidly desensitizing allergic patients |
| 05/16/2013 | WO2012166884A3 Encapsulated polar materials and methods of preparation |
| 05/16/2013 | WO2012163937A3 Solid solutions of polyphenols |
| 05/16/2013 | US20130125259 Rna interference mediating small rna molecules |
| 05/16/2013 | US20130123742 Method of a Pharmaceutical Delivery System for Use Within a Joint Replacement |
| 05/16/2013 | US20130123720 Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid |
| 05/16/2013 | US20130123707 Aqueous formulations for coating microneedle arrays |
| 05/16/2013 | US20130123373 Use Of Polyether-Based And Vinyl Monomer-Based Copolymers As Binders For Dosing Forms Comprising Solid Active Ingredients |
| 05/16/2013 | US20130123362 Type a gelatin capsule containing pufa in free acid form |
| 05/16/2013 | US20130123314 Method for improving cartilage repair and/or preventing cartilage degeneration in a joint |
| 05/16/2013 | US20130123294 Formulations containing nalbuphine and uses thereof |
| 05/16/2013 | US20130123292 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| 05/16/2013 | US20130123220 Stable Topical Composition and a Process for Producing a Stable Topical Composition |
| 05/16/2013 | US20130123218 Intravenous Formulation with Water-soluble CoCrystals of Acetylsalicylic Acid and Theanine |
| 05/16/2013 | US20130123179 Fast dissolving pharmaceutical composition |
| 05/16/2013 | US20130123095 Orally administered adsorbent, method of producing the same, and drug produced by using the same |
| 05/16/2013 | US20130122295 Allergen suppressor, allergen-suppression processed fiber and method of producing the same |
| 05/16/2013 | US20130122171 Dietary Fiber Composition |
| 05/16/2013 | US20130122124 Mucosal formulation |
| 05/16/2013 | US20130122106 Dosage form, and methods of making and using the same, to produce immunization in animals and humans |
| 05/16/2013 | US20130122105 Methods and Compositions for Gene Therapy and GHRH Therapy |
| 05/16/2013 | US20130122103 Electrostatically bonded vesicle |
| 05/16/2013 | US20130122102 Delivery Systems For Improving Oral Bioavailability of Fenobam, Its Hydrates, And Salts |
| 05/16/2013 | US20130122101 Abuse resistant drug formulation |
| 05/16/2013 | US20130122100 Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| 05/16/2013 | US20130122099 Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| 05/16/2013 | US20130122098 Method and composition to improve absorption of therapeutic agents |
| 05/16/2013 | US20130122097 Antifungal therapy |
| 05/16/2013 | US20130122096 Compositions for drug delivery and methods of manufacturing and using same |
| 05/16/2013 | US20130122095 Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
| 05/16/2013 | US20130122092 Three-phase controlled-release tablet comprising melatonin and process of preparation |
| 05/16/2013 | US20130122090 Multiple Unit Tablet Composition |
| 05/16/2013 | US20130122089 Dpp iv inhibitor formulations |
| 05/16/2013 | US20130122088 Tablet formulations containing 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
| 05/16/2013 | US20130122087 Abuse resistant drug formulation |
| 05/16/2013 | US20130122086 Method for treating celiac disease |
| 05/16/2013 | US20130122081 Liposomes useful for drug delivery |
| 05/16/2013 | US20130122080 Pharmaceutical composition capable of immuno-regulation or enhancement of immune response |
| 05/16/2013 | US20130122077 Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery |